SEC Form 4 · accession 0000899243-18-013665
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
May 18, 2018
Accepted (ET)
May 22, 2018 · 3:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 18, 2018 | P | 50,000 | $42.2402 | A | 2,872,964 | D | |
| Common Stock | May 21, 2018 | P | 80,000 | $38.772 | A | 2,952,964 | D |
Table II — derivative securities
No Table II lines on this filing.
Remarks
Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Esperion Therapeutics, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.